MK-677 (Ibutamoren) and Levothyroxine Interaction: Safety, Risks, and Monitoring

MK-677, also called ibutamoren, is an orally active ghrelin receptor agonist that raises growth hormone (GH) and IGF-1 levels. It is not FDA-approved for any indication and is currently sold outside the regulated drug supply as a research chemical. Levothyroxine (brand names include Synthroid and Euthyrox) is an FDA-approved synthetic thyroid hormone (T4) used to treat hypothyroidism and has a narrow therapeutic index, meaning small changes in exposure can produce clinically meaningful effects.

There is no documented pharmacokinetic interaction between ibutamoren and levothyroxine: the two do not compete for the same metabolic enzymes or transporters. The concern is pharmacodynamic. GH physiology is known to influence thyroid hormone economy, and a person taking levothyroxine who starts a GH-raising compound may need thyroid function rechecked and the dose adjusted. This has been demonstrated for injectable GH replacement therapy in growth-hormone-deficient adults. It has not been specifically studied for ibutamoren, and the magnitude of any effect from an oral GH secretagogue at typical research-use doses is not established.

What can be said with confidence today: GH elevation, from any source, has a documented tendency to alter thyroid hormone requirements in people on levothyroxine, through effects on peripheral T4-to-T3 conversion and pituitary TSH regulation. This is established for exogenous GH therapy in growth-hormone-deficient patients, not specifically for ibutamoren. Whether ibutamoren's milder, orally-stimulated GH pulses produce a clinically meaningful shift in levothyroxine requirements has not been directly tested in a published trial. Anyone combining the two should treat a TSH check 6 to 8 weeks after starting, stopping, or changing the dose of ibutamoren as a reasonable, low-risk precaution rather than an optional step, and should raise the combination with the prescribing clinician before assuming stability.

Why the GH-thyroid connection matters here

The hypothalamic-pituitary axis regulates GH and thyroid-stimulating hormone (TSH) through overlapping feedback loops. GH is known to increase activity of the deiodinase enzymes that convert T4 to the more active T3 in peripheral tissue, and elevated GH raises hypothalamic somatostatin tone, which can blunt TSH secretion at the pituitary. Both effects have been described in the physiology and endocrinology literature on GH-deficient adults receiving recombinant GH replacement. Because levothyroxine only supplies T4, a person who cannot make additional endogenous thyroid hormone has less ability to compensate if peripheral conversion accelerates.

This is the reason thyroid function monitoring is a standard part of GH replacement therapy in medical practice, and it is the reasoning basis, not a demonstrated fact, for expecting a similar though probably smaller effect from ibutamoren.

The mechanism, and where it is extrapolated rather than proven

Two mechanisms are commonly cited to explain a GH-thyroid interaction:

Accelerated T4-to-T3 conversion. GH elevation is associated with increased deiodinase activity, which converts T4 to T3 in peripheral tissue. In a patient on levothyroxine alone, faster conversion can deplete circulating T4 faster than the fixed daily dose replaces it, which over time can push TSH upward if the levothyroxine dose is not increased.

Somatostatin-mediated TSH suppression. GH elevation raises somatostatin tone, and somatostatin directly inhibits pituitary TSH release. This could transiently lower measured TSH in the first one to two weeks of a new GH secretagogue, independent of actual thyroid hormone adequacy.

Evidence-status assessment: MK-677 and levothyroxine

What a prescriber or pharmacist should verify before acting on this page: the current FDA label language for the specific levothyroxine product in use, any newer published data specifically studying ibutamoren and thyroid function, and the patient's baseline thyroid reserve (athyreotic versus residual function) before deciding whether a preemptive levothyroxine adjustment is warranted versus a monitor-and-adjust approach.

Who is likely to need closer monitoring

People with no residual thyroid tissue, such as after thyroidectomy or radioactive iodine ablation, have no ability to compensate for faster T4 clearance and are the group most likely to need a levothyroxine dose review if they start a GH-raising compound. People whose TSH is already at the upper edge of the target range before starting ibutamoren have less buffer than someone with a well-centered TSH. Older adults, who often have reduced thyroid hormone clearance reserve generally, may also warrant closer attention, though this has not been specifically studied for ibutamoren.

People with intact thyroid glands who are not on levothyroxine have their own gland available to compensate for any GH-driven shift in hormone handling, and are less likely to develop a clinically significant change, though this should not be assumed without at least baseline awareness if GH-raising compounds are used long term.

Levothyroxine timing and absorption

Levothyroxine absorption is well documented to be reduced by calcium supplements, iron, coffee, high-fiber meals, and proton pump inhibitors. Standard clinical guidance is to take levothyroxine on an empty stomach, roughly 30 to 60 minutes before food, coffee, or other oral medications and supplements.

No chelation or binding interaction between ibutamoren and levothyroxine has been documented, and ibutamoren does not contain the polyvalent cations known to interfere with levothyroxine absorption. Even so, the standard levothyroxine timing rule applies regardless of what else a patient is taking. A practical approach some clinicians use: levothyroxine first thing in the morning on an empty stomach, ibutamoren at a separate time such as bedtime. This also makes it easier to attribute a later TSH change to the hormonal-axis interaction rather than to an absorption problem, since the two are no longer co-administered.

A reasonable monitoring approach

Growth hormone replacement guidelines from specialty endocrine societies generally call for baseline thyroid function testing before starting GH-axis therapy and periodic rechecks afterward, since GH replacement is a recognized cause of increased levothyroxine requirements. Ibutamoren has not been studied under a comparable monitoring protocol, so the following adapts that general principle rather than restating a guideline written specifically for ibutamoren:

Before starting ibutamoren: document current TSH, free T4, and the levothyroxine dose. Note whether the patient has any residual thyroid function.

Around 6 to 8 weeks after starting, or after any dose change: recheck TSH and free T4. A rise in TSH above the individual's prior stable range, or a fall in free T4, is a reasonable trigger to discuss a levothyroxine dose adjustment with the prescribing clinician rather than a fixed numeric threshold, since no validated threshold specific to ibutamoren exists.

After that: continue monitoring at intervals the prescribing clinician judges appropriate until thyroid values are stable on an unchanged dose, then return to routine thyroid monitoring frequency.

If ibutamoren is stopped: recheck TSH again in a similar window, since a levothyroxine dose that was raised to compensate for ibutamoren's effect could become excessive once the GH stimulus is removed, with a risk of over-replacement symptoms such as palpitations, tremor, anxiety, or accelerated bone loss with prolonged excess.

Any specific dose-adjustment increment (such as a defined microgram amount) is an individualized clinical decision that depends on the person's weight, baseline TSH, cardiac history, and other factors, and should not be taken from a general article. This article does not provide individualized dosing guidance.

Glucose and metabolic overlap

GH is a counter-regulatory hormone that opposes insulin action, and GH-raising compounds including ibutamoren have been associated with increases in fasting glucose and insulin in published trials of GH secretagogues. Undertreated hypothyroidism separately impairs glucose handling. If a GH-thyroid interaction causes a person to become functionally more hypothyroid, the two effects on glucose metabolism could plausibly compound, though the size of this combined effect in ibutamoren users specifically has not been quantified in the material reviewed here. People with prediabetes or type 2 diabetes who are also on levothyroxine and considering ibutamoren should discuss added glucose monitoring with their clinician.

Regulatory status of MK-677

MK-677 (ibutamoren) has never received FDA approval for any indication. It was studied by Merck in the late 1990s and early 2000s for growth hormone deficiency, sarcopenia, and recovery after hip fracture, but did not advance to marketing approval. It is currently distributed as a research chemical, frequently alongside SARMs (selective androgen receptor modulators), and is not subject to pharmaceutical manufacturing quality controls. Regulators have previously warned against using SARMs and related body-building products, noting safety and quality concerns with this category of unregulated compounds. Levothyroxine, by contrast, is an FDA-approved prescription medication with an approved labeling document that should be consulted directly for current interaction and monitoring language.

Anyone using ibutamoren obtained outside a licensed pharmacy should tell their prescribing clinician, since product purity and actual dose delivered cannot be verified the way they can for an approved pharmaceutical.

Other reported pharmacodynamic interactions with MK-677

Glucocorticoids can blunt GH secretion and may partially offset ibutamoren's GH-raising effect while independently raising glucose, an additive concern for glucose control. Dopamine agonists such as cabergoline or bromocriptine suppress GH and could reduce ibutamoren's intended effect. Insulin and sulfonylureas may need dose review given ibutamoren's insulin-antagonizing tendency. Ibutamoren is believed to be metabolized in part through CYP3A4, so strong CYP3A4 inhibitors could theoretically raise ibutamoren exposure, but no formal drug-drug interaction study has established the size of this effect, and this should be treated as a theoretical caution rather than a quantified risk.

Because ibutamoren has no FDA-approved label, none of its interactions have been studied using standard regulatory drug-interaction methodology. All of the interaction reasoning above is extrapolated from GH physiology and from data on other GH-raising therapies, not from dedicated ibutamoren interaction trials.

When to seek care rather than wait for a scheduled recheck

New or worsening fatigue, cold intolerance, constipation, unexplained weight gain, or puffiness after starting ibutamoren can reflect worsening hypothyroidism and warrant an earlier TSH check rather than waiting for a routine visit. Palpitations, tremor, unexplained weight loss, heat intolerance, or anxiety could reflect thyroid hormone excess, particularly if ibutamoren is stopped without a levothyroxine dose review. Chest pain, significant shortness of breath, or signs of a hyperthyroid or hypothyroid emergency warrant urgent evaluation rather than a routine outpatient recheck.

What is established, what is plausible, and what remains unknown

Established: GH elevation from recognized GH replacement therapy alters thyroid hormone handling and levothyroxine requirements in growth-hormone-deficient adults, and levothyroxine absorption is sensitive to timing and co-administered substances. Plausible, based on shared physiology, but not directly demonstrated for ibutamoren: a comparable, likely smaller, shift in thyroid hormone handling in people taking ibutamoren while on levothyroxine, and a compounding effect on glucose metabolism in people with both undertreated hypothyroidism and ibutamoren-related insulin resistance. Not established: any specific numeric threshold, timeline, or dose-adjustment increment specific to ibutamoren and levothyroxine, since no dedicated interaction trial for this combination was identified.

People on levothyroxine who are using or considering ibutamoren should discuss the combination with their prescribing clinician or pharmacist, disclose the ibutamoren use explicitly since it will not appear in a standard medication reconciliation, and plan for a thyroid function recheck after starting, changing, or stopping ibutamoren rather than assuming a stable dose will remain adequate.

References

• Current FDA-approved prescribing information for the specific levothyroxine product in use should be consulted directly for authoritative interaction and monitoring language; the specific label edition should be verified rather than assumed.
• Primary literature specific to ibutamoren's effects on thyroid function and its interaction with levothyroxine was not independently verifiable at the time of this review. Claims describing GH replacement's effect on thyroid hormone handling reflect general endocrinology practice regarding GH-deficient adults on recombinant GH therapy; a qualified reviewer should confirm current primary sources before this article is published in final form.